BRICKELL BIOTECH
Brickell Biotech, Inc. is a clinical-stage pharmaceutical company focused on the development of innovative and differentiated prescription therapeutics for debilitating skin diseases with a focus on its lead asset sofpironium bromide for the treatment of hyperhidrosis. Brickell’s executive management team and board of directors bring extensive experience in product development and global commercialization, having served in leadership roles at large global pharmaceutical companies and biotechs that have developed and/or launched successful products, including several that were first-in-class and/or achieved iconic status, such as Cialis®, Taltz®, Gemzar®, Prozac®, Cymbalta® and Juvederm®.
BRICKELL BIOTECH
Social Links:
Industry:
Biotechnology Health Care Therapeutics
Founded:
2009-01-01
Address:
Miami, Florida, United States
Country:
United States
Website Url:
http://www.brickellbio.com
Total Employee:
11+
Status:
Active
Contact:
7865242721
Email Addresses:
[email protected]
Total Funding:
33.46 M USD
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SPF SSL By Default Google Font API Google Analytics LetsEncrypt Apple Mobile Web Clips Icon Google Tag Manager WordPress
Similar Organizations
Apellis Pharmaceuticals
Apellis Pharmaceuticals focuses on developing novel therapeutics and drug delivery technologies to address chronic inflammatory diseases.
Excision BioTherapeutics
Excision is developing CRISPR-based therapies to cure viral infectious diseases and improve the lives of chronically ill patients.
Passage Bio
Passage Bio is a fully integrated gene therapy company developing therapies for the treatment of monogenic central nervous system diseases.
Current Advisors List
Current Employees Featured
Founder
Stock Details
Acquisitions List
| Date | Company | Article | Price |
|---|---|---|---|
| 2019-06-03 | Vical | Vical acquired by Brickell Biotech | N/A |
Investors List
Charlie Stiefel
Charlie Stiefel investment in Series C - Brickell Biotech
AMOREPACIFIC Ventures
AMOREPACIFIC Ventures investment in Series B - Brickell Biotech
Palisade Capital Management
Palisade Capital Management investment in Series B - Brickell Biotech
Key Employee Changes
| Date | New article |
|---|---|
| 2021-09-01 | Brickell Biotech Expands Leadership Team, Appointing Dr. Monica Luchi as Chief Medical Officer |
Official Site Inspections
http://www.brickellbio.com Semrush global rank: 2.28 M Semrush visits lastest month: 8.3 K
- Host name: 172.67.223.96
- IP address: 172.67.223.96
- Location: United States
- Latitude: 37.751
- Longitude: -97.822
- Timezone: America/Chicago
More informations about "Brickell Biotech"
Brickell Biotech, Inc - Brickell Biotech, Inc. is a clinical-stage ...
We use first and third party cookies to obtain statistical information to personalize our website and provide you with a better experience. If you continue without changing your settings, this …See details»
Company - Brickell Biotech, Inc
Brickell Biotech, Inc. is a clinical-stage pharmaceutical company striving to transform patient lives by developing innovative and differentiated prescription therapeutics for the treatment of …See details»
Brickell Biotech - Crunchbase Company Profile & Funding
Contact Email [email protected] Phone Number 7865242721 Brickell Biotech, Inc. is a clinical-stage pharmaceutical company focused on the development of innovative and differentiated …See details»
Brickell Biotech Company Profile | Management and Employees …
Www.brickellbio.com . Brickell Biotech Profile and History. Brickell Biotech, Inc. is a clinical-stage pharmaceutical company focused on developing innovative and differentiated prescription …See details»
Corporate Governance :: Brickell Biotech, Inc. (BBI)
Rob Brown joins Brickell as Chief Executive Officer, after having spent over 30 years at Eli Lilly and Company, where he most recently served as chief marketing officer (CMO) and senior …See details»
Brickell Biotech, Inc. - Cruelty Free Investing
Company Website: https://brickellbio.com Contact: [email protected] ©2024 CrueltyFreeInvesting.org | Cruelty Free Investing is a registered 501c3 Non-Profit Organization …See details»
Brickell Biotech, Inc. Overview | SignalHire Company Profile
Phone Number (720) 505-4755: Brickell Biotech, Inc. industries Pharma, Pharmaceuticals: Headquarters LocationSee details»
Brickell Biotech Announces Corporate Rebranding to Fresh Tracks ...
The introduction of the Fresh Tracks Therapeutics brand is designed to represent the Company’s fresh vision and development strategy. The unveiling of the Company’s rebranding reinforces …See details»
Brickell Biotech - VentureRadar
Brickell Biotech, Inc. is a development-stage pharmaceutical company focused on the acquisition, development and commercialization of innovative drug... ... Find out ...See details»
BrickellBio’s Competitors, Revenue, Number of Employees ... - Owler
BrickellBio’s Profile, Revenue and Employees. Brickell is a Colorado-based clinical-stage pharmaceutical company that researches and develops therapeutics for the treatment of …See details»
Brickell Biotech Company Profile: Overview and Full News Analysis
News Summary Voronoi, a Korean biotech startup, has clinched a $324 million deal to grant Brickell Biotech access to a platform of inhibitors targeting neuroinflammatory and other …See details»
Brickell Bio – VisionTech Partners
Brickell Bio is a clinical stage pharmaceutical company focused on developing innovative and differentiated therapeutics for treating skin diseases. Brickell’s lead pipeline asset, sofpironium …See details»
BrickellBio - Company, United States - SWFI - Sovereign Wealth …
BrickellBio: Company in United States, North America BrickellBio is a Company located in United States, North America, and was founded in 2009. Request Profile UpdateSee details»
Brickell Biotech to Report Fourth Quarter and Full Year 2020 …
BOULDER, Colo., Feb. 23, 2021 (GLOBE NEWSWIRE) -- Brickell Biotech, Inc. (“Brickell”) (Nasdaq: BBI), a clinical-stage pharmaceutical company focused on developing innovative and …See details»
Brickell Biotech Acquires Exclusive Rights to Phase 1-Ready …
Sep 1, 2021 Expect to initiate Phase 1 clinical study of lead DYRK1A inhibitor program, BBI-02, a potential first-in-class oral treatment for autoimmune and inflammatory diseases, in 2022 …See details»
Brickell Biotech Inc. (BBI) $1.73 (NASDAQ) Share Price Today
Website https://www.brickellbio.com; Business. Brickell Biotech, Inc., a clinical-stage pharmaceutical company, engages in the... development of various prescription therapeutics …See details»
Join Us - Brickell Biotech, Inc
WORKING WITH BRICKELL BIO. Brickell prides itself on bringing fresh, innovative ideas to the pharmaceutical industry. Our dynamic team strives to provide patients young and old with …See details»
Brickell Biotech nabs autoimmune, inflammatory program
Sep 1, 2021 RELATED: Lilly's Robert Brown to lead Brickell Bio as it eyes phase 3 dermatology trials. Brickell is paying Voronoi $2.5 million in cash and $2.5 million in stock upfront, with $211 …See details»
Brickell Biotech Announces Final Patient Completed Second U.S.
Aug 16, 2021 Further information on the factors and risks that could cause actual results to differ from any forward-looking statements are contained in Brickell’s filings with the United States …See details»
Brickell Bio’s Development Partner, Kaken Pharmaceutical, Submits …
BOULDER, Colo., Jan. 10, 2020 (GLOBE NEWSWIRE) -- Brickell Biotech, Inc. (“Brickell”) (Nasdaq: BBI), a clinical-stage pharmaceutical company focused on developing innovative and …See details»